Clinical applications of neuroimaging in patients with Alzheimer's disease: a review from the Fourth Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012.

Abstract:

:In May 2012, the Fourth Canadian Consensus Conference on the Diagnosis and Treatment of Dementia brought together in Montreal experts from around Canada to update Canadian recommendations for the diagnosis and management of patients with neurodegenerative conditions associated with deterioration of cognition. Multiple topics were discussed. The present paper is a highly condensed version of those recommendations that were produced to support discussions in the field of neuroimaging for clinical diagnosis of those conditions.

journal_name

Alzheimers Res Ther

authors

Soucy JP,Bartha R,Bocti C,Borrie M,Burhan AM,Laforce R,Rosa-Neto P

doi

10.1186/alzrt199

subject

Has Abstract

pub_date

2013-07-08 00:00:00

pages

S3

issue

Suppl 1

issn

1758-9193

pii

alzrt199

journal_volume

5

pub_type

杂志文章
  • Cognitive training and brain stimulation in prodromal Alzheimer's disease (AD-Stim)-study protocol for a double-blind randomized controlled phase IIb (monocenter) trial.

    abstract:BACKGROUND:Given the growing older population worldwide, and the associated increase in age-related diseases, such as Alzheimer's disease (AD), investigating non-invasive methods to ameliorate or even prevent cognitive decline in prodromal AD is highly relevant. Previous studies suggest transcranial direct current stim...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-020-00692-5

    authors: Thams F,Kuzmina A,Backhaus M,Li SC,Grittner U,Antonenko D,Flöel A

    更新日期:2020-11-07 00:00:00

  • A single dose of the γ-secretase inhibitor semagacestat alters the cerebrospinal fluid peptidome in humans.

    abstract:BACKGROUND:In Alzheimer's disease, beta-amyloid peptides in the brain aggregate into toxic oligomers and plaques, a process which is associated with neuronal degeneration, memory loss, and cognitive decline. One therapeutic strategy is to decrease the production of potentially toxic beta-amyloid species by the use of i...

    journal_title:Alzheimer's research & therapy

    pub_type: 临床试验,杂志文章

    doi:10.1186/s13195-016-0178-x

    authors: Hölttä M,Dean RA,Siemers E,Mawuenyega KG,Sigurdson W,May PC,Holtzman DM,Portelius E,Zetterberg H,Bateman RJ,Blennow K,Gobom J

    更新日期:2016-03-07 00:00:00

  • Subjective cognitive decline and subsequent dementia: a nationwide cohort study of 579,710 people aged 66 years in South Korea.

    abstract:BACKGROUND:Subjective cognitive decline (SCD) is a potential risk factor for dementia. We aimed to investigate the association between SCD and subsequent dementia in a nationwide population-based cohort in South Korea. METHODS:This cohort included 579,710 66-year-old adults who were followed for a total of 3,870,293 p...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-020-00618-1

    authors: Lee YC,Kang JM,Lee H,Kim K,Kim S,Yu TY,Lee EM,Kim CT,Kim DK,Lewis M,Won HH,Jessen F,Myung W

    更新日期:2020-05-06 00:00:00

  • Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer's disease.

    abstract:BACKGROUND:Down syndrome (DS), caused by chromosome 21 trisomy, is associated with an ultra-high risk of dementia due to Alzheimer's disease (AD), driven by amyloid precursor protein (APP) gene triplication. Understanding relevant molecular differences between those with DS, those with sporadic AD (sAD) without DS, and...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-019-0477-0

    authors: Startin CM,Ashton NJ,Hamburg S,Hithersay R,Wiseman FK,Mok KY,Hardy J,Lleó A,Lovestone S,Parnetti L,Zetterberg H,Hye A,LonDownS Consortium.,Strydom A

    更新日期:2019-03-21 00:00:00

  • Clinical subtypes of chronic traumatic encephalopathy: literature review and proposed research diagnostic criteria for traumatic encephalopathy syndrome.

    abstract::The long-term consequences of repetitive head impacts have been described since the early 20th century. Terms such as punch drunk and dementia pugilistica were first used to describe the clinical syndromes experienced by boxers. A more generic designation, chronic traumatic encephalopathy (CTE), has been employed sinc...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章,评审

    doi:10.1186/s13195-014-0068-z

    authors: Montenigro PH,Baugh CM,Daneshvar DH,Mez J,Budson AE,Au R,Katz DI,Cantu RC,Stern RA

    更新日期:2014-09-24 00:00:00

  • Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer's Disease.

    abstract::The cerebrospinal fluid (CSF) biochemical markers (biomarkers) Amyloidβ 42 (Aβ42), total Tau (T-tau) and Tau phosphorylated at threonine 181 (P-tau181) have proven diagnostic accuracy for mild cognitive impairment and dementia due to Alzheimer's Disease (AD). In an effort to improve the accuracy of an AD diagnosis, it...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章,评审

    doi:10.1186/s13195-019-0485-0

    authors: Hansson O,Lehmann S,Otto M,Zetterberg H,Lewczuk P

    更新日期:2019-04-22 00:00:00

  • Active immunotherapy options for Alzheimer's disease.

    abstract::Alzheimer's disease (AD) is the most common cause of dementia and a major contributor to disability and dependency among older people. AD pathogenesis is associated with the accumulation of amyloid-beta protein (Aβ) and/or hyperphosphorylated tau protein in the brain. At present, current therapies provide temporary sy...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章,评审

    doi:10.1186/alzrt237

    authors: Winblad B,Graf A,Riviere ME,Andreasen N,Ryan JM

    更新日期:2014-01-30 00:00:00

  • Should interventions to treat or prevent Alzheimer's disease be tested in a population or as targeted treatment of highly selected study participants?

    abstract::Symptomatic treatments for Alzheimer's disease should retain a place in the advanced stages of disease since their actions on these symptoms, even if not modifying the course of disease, are critical for improving patients' comfort and reducing the burden felt by caregivers, especially those facing behavioral disorder...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/alzrt228

    authors: Ousset PJ,Delrieu J,Vellas B

    更新日期:2013-12-11 00:00:00

  • Towards a unified protocol for handling of CSF before β-amyloid measurements.

    abstract:BACKGROUND:Widespread implementation of Alzheimer's disease biomarkers in routine clinical practice requires the establishment of standard operating procedures for pre-analytical handling of cerebrospinal fluid (CSF). METHODS:Here, CSF collection and storage protocols were optimized for measurements of β-amyloid (Aβ)....

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-019-0517-9

    authors: Janelidze S,Stomrud E,Brix B,Hansson O

    更新日期:2019-07-19 00:00:00

  • Differential effects of chronic immunosuppression on behavioral, epigenetic, and Alzheimer's disease-associated markers in 3xTg-AD mice.

    abstract:BACKGROUND:Circulating autoantibodies and sex-dependent discrepancy in prevalence are unexplained phenomena of Alzheimer's disease (AD). Using the 3xTg-AD mouse model, we reported that adult males show early manifestations of systemic autoimmunity, increased emotional reactivity, enhanced expression of the histone vari...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-020-00745-9

    authors: Kapadia M,Mian MF,Ma D,Hutton CP,Azam A,Narkaj K,Cao C,Brown B,Michalski B,Morgan D,Forsythe P,Zovkic IB,Fahnestock M,Sakic B

    更新日期:2021-01-20 00:00:00

  • The effects of different familial Alzheimer's disease mutations on APP processing in vivo.

    abstract:BACKGROUND:Disturbed amyloid precursor protein (APP) processing is considered to be central to the pathogenesis of Alzheimer's disease (AD). The autosomal dominant form of the disease, familial AD (FAD), may serve as a model for the sporadic form of AD. In FAD the diagnosis of AD is reliable and presymptomatic individu...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-017-0234-1

    authors: Thordardottir S,Kinhult Ståhlbom A,Almkvist O,Thonberg H,Eriksdotter M,Zetterberg H,Blennow K,Graff C

    更新日期:2017-02-16 00:00:00

  • Systematic reviews on behavioural and psychological symptoms in the older or demented population.

    abstract:INTRODUCTION:Behavioural and psychological symptoms of dementia (BPS) include depressive symptoms, anxiety, apathy, sleep problems, irritability, psychosis, wandering, elation and agitation, and are common in the non-demented and demented population. METHODS:We have undertaken a systematic review of reviews to give a ...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/alzrt131

    authors: van der Linde RM,Stephan BC,Savva GM,Dening T,Brayne C

    更新日期:2012-07-11 00:00:00

  • Generation of a new transgenic mouse model for assessment of tau gene silencing therapies.

    abstract:BACKGROUND:Targeting the expression of genes has emerged as a potentially viable therapeutic approach to human disease. In Alzheimer's disease, therapies that silence the expression of tau could be a viable strategy to slow disease progression. METHODS:We produced a novel strain of transgenic mice that could be used t...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-016-0202-1

    authors: Fromholt S,Reitano C,Brown H,Lewis J,Borchelt DR

    更新日期:2016-09-05 00:00:00

  • Assessment of kallikrein 6 as a cross-sectional and longitudinal biomarker for Alzheimer's disease.

    abstract:BACKGROUND:Kallikrein 6 (KLK6) is known to be an age-related protease expressed at high levels in the central nervous system. It was previously shown to be involved in proteolysis of extracellular proteins implicated in neurodegenerative diseases such as Alzheimer's disease (AD), prompting validation of KLK6 as a poten...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-018-0336-4

    authors: Patra K,Soosaipillai A,Sando SB,Lauridsen C,Berge G,Møller I,Grøntvedt GR,Bråthen G,Begcevic I,Moussaud S,Minthon L,Hansson O,Diamandis EP,White LR,Nielsen HM

    更新日期:2018-01-29 00:00:00

  • Efficient clearance of Aβ protofibrils in AβPP-transgenic mice treated with a brain-penetrating bifunctional antibody.

    abstract:BACKGROUND:Amyloid-β (Aβ) immunotherapy is one of the most promising disease-modifying strategies for Alzheimer's disease (AD). Despite recent progress targeting aggregated forms of Aβ, low antibody brain penetrance remains a challenge. In the present study, we used transferrin receptor (TfR)-mediated transcytosis to f...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-018-0377-8

    authors: Syvänen S,Hultqvist G,Gustavsson T,Gumucio A,Laudon H,Söderberg L,Ingelsson M,Lannfelt L,Sehlin D

    更新日期:2018-05-24 00:00:00

  • Communicating mild cognitive impairment diagnoses with and without amyloid imaging.

    abstract:BACKGROUND:Mild cognitive impairment (MCI) has an uncertain etiology and prognosis and may be challenging for clinicians to discuss with patients and families. Amyloid imaging may aid specialists in determining MCI etiology and prognosis, but creates novel challenges related to disease labeling. METHODS:We convened a ...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章,评审

    doi:10.1186/s13195-017-0261-y

    authors: Grill JD,Apostolova LG,Bullain S,Burns JM,Cox CG,Dick M,Hartley D,Kawas C,Kremen S,Lingler J,Lopez OL,Mapstone M,Pierce A,Rabinovici G,Roberts JS,Sajjadi SA,Teng E,Karlawish J

    更新日期:2017-05-04 00:00:00

  • Alzheimer's disease drug-development pipeline: few candidates, frequent failures.

    abstract:INTRODUCTION:Alzheimer's disease (AD) is increasing in frequency as the global population ages. Five drugs are approved for treatment of AD, including four cholinesterase inhibitors and an N-methyl-D-aspartate (NMDA)-receptor antagonist. We have an urgent need to find new therapies for AD. METHODS:We examined Clinical...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/alzrt269

    authors: Cummings JL,Morstorf T,Zhong K

    更新日期:2014-07-03 00:00:00

  • Progression to dementia in memory clinic patients with mild cognitive impairment and normal β-amyloid.

    abstract:BACKGROUND:Determination of β-amyloid (Aβ) positivity and likelihood of underlying Alzheimer's disease (AD) relies on dichotomous biomarker cut-off values. Individuals with mild cognitive impairment (MCI) and Aβ within the normal range may still have a substantial risk of developing dementia, primarily of Alzheimer typ...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-019-0557-1

    authors: Rosenberg A,Solomon A,Jelic V,Hagman G,Bogdanovic N,Kivipelto M

    更新日期:2019-12-05 00:00:00

  • Risk of head and traumatic brain injuries associated with antidepressant use among community-dwelling persons with Alzheimer's disease: a nationwide matched cohort study.

    abstract:BACKGROUND:Antidepressant use has been associated with an increased risk of falling, but no studies have been conducted on whether antidepressant use is associated with an increased risk of head injuries which often result from falling among older persons. The objective of this study was to investigate the risk of head...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-017-0285-3

    authors: Taipale H,Koponen M,Tanskanen A,Lavikainen P,Sund R,Tiihonen J,Hartikainen S,Tolppanen AM

    更新日期:2017-08-01 00:00:00

  • Recommendations for cerebrospinal fluid collection for the analysis by ELISA of neurogranin trunc P75, α-synuclein, and total tau in combination with Aβ(1-42)/Aβ(1-40).

    abstract:BACKGROUND:The pathophysiology of neurodegeneration is complex. Its diagnosis requires an early identification of sequential changes in several hallmarks in the brains of affected subjects. The presence of brain pathology can be visualized in the cerebrospinal fluid (CSF) by protein profiling. It is clear that the fiel...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-017-0265-7

    authors: Vanderstichele H,Demeyer L,Janelidze S,Coart E,Stoops E,Mauroo K,Herbst V,François C,Hansson O

    更新日期:2017-06-06 00:00:00

  • The association of vascular disorders with incident dementia in different age groups.

    abstract:BACKGROUND:There is increasing evidence that dementia risk associated with vascular disorders is age dependent. Large population-based studies of incident dementia are necessary to further elucidate this effect. Therefore, the aim of the present study was to determine the association of vascular disorders with incident...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-019-0496-x

    authors: Legdeur N,van der Lee SJ,de Wilde M,van der Lei J,Muller M,Maier AB,Visser PJ

    更新日期:2019-05-17 00:00:00

  • Alzheimer's Disease Assessment Scale-Cognitive subscale variants in mild cognitive impairment and mild Alzheimer's disease: change over time and the effect of enrichment strategies.

    abstract:BACKGROUND:Development of new treatments for Alzheimer's disease (AD) has broadened into early interventions in individuals with modest cognitive impairment and a slow decline. The 11-item version of the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog) was originally developed to measure cognition in ...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-016-0170-5

    authors: Podhorna J,Krahnke T,Shear M,Harrison JE,Alzheimer’s Disease Neuroimaging Initiative.

    更新日期:2016-02-12 00:00:00

  • Posterior atrophy predicts time to dementia in patients with amyloid-positive mild cognitive impairment.

    abstract:BACKGROUND:In patients with amyloid-positive mild cognitive impairment (MCI), neurodegenerative biomarkers such as medial temporal lobe atrophy (MTA) are useful to predict disease progression to dementia. Although posterior atrophy (PA) is a well-known neurodegenerative biomarker of Alzheimer's disease, little is known...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-017-0326-y

    authors: Pyun JM,Park YH,Kim HR,Suh J,Kang MJ,Kim BJ,Youn YC,Jang JW,Kim S,Alzheimer’s Disease Neuroimaging Initiative.

    更新日期:2017-12-16 00:00:00

  • Biomarkers in biological fluids for dementia with Lewy bodies.

    abstract::Dementia with Lewy bodies (DLB) has become the second most common neurodegenerative dementia due to demographic ageing. Differential diagnosis is still troublesome especially in early stages of the disease, since there is a great clinical and neuropathological overlap primarily with Alzheimer's disease and Parkinson's...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章,评审

    doi:10.1186/s13195-014-0072-3

    authors: Schade S,Mollenhauer B

    更新日期:2014-10-16 00:00:00

  • In vivo quantification of neurofibrillary tangles with [18F]MK-6240.

    abstract:BACKGROUND:Imaging agents capable of quantifying the brain's tau aggregates will allow a more precise staging of Alzheimer's disease (AD). The aim of the present study was to examine the in vitro properties as well as the in vivo kinetics, using gold standard methods, of the novel positron emission tomography (PET) tau...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-018-0402-y

    authors: Pascoal TA,Shin M,Kang MS,Chamoun M,Chartrand D,Mathotaarachchi S,Bennacef I,Therriault J,Ng KP,Hopewell R,Bouhachi R,Hsiao HH,Benedet AL,Soucy JP,Massarweh G,Gauthier S,Rosa-Neto P

    更新日期:2018-07-31 00:00:00

  • Statins and therapy of Alzheimer's disease: questions of efficacy versus trial design.

    abstract::Recent trials of statins produced no benefit for subjects with Alzheimer's disease. These negative studies add to a growing list of negative clinical trials. These data point to a need for reevaluating the pathophysiology of late-onset Alzheimer's disease. Late-onset Alzheimer's disease might result from the cumulativ...

    journal_title:Alzheimer's research & therapy

    pub_type: 社论

    doi:10.1186/alzrt101

    authors: Wolozin B

    更新日期:2012-01-16 00:00:00

  • Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers.

    abstract:BACKGROUND:The Centiloid scale has been developed to standardize measurements of amyloid PET imaging. Reference cut-off values of this continuous measurement enable the consistent operationalization of decision-making for multicentre research studies and clinical trials. In this study, we aimed at deriving reference Ce...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-019-0478-z

    authors: Salvadó G,Molinuevo JL,Brugulat-Serrat A,Falcon C,Grau-Rivera O,Suárez-Calvet M,Pavia J,Niñerola-Baizán A,Perissinotti A,Lomeña F,Minguillon C,Fauria K,Zetterberg H,Blennow K,Gispert JD,Alzheimer’s Disease Neuroimaging Init

    更新日期:2019-03-21 00:00:00

  • Brain metabolism and cerebrospinal fluid biomarkers profile of non-amnestic mild cognitive impairment in comparison to amnestic mild cognitive impairment and normal older subjects.

    abstract:INTRODUCTION:Mild cognitive impairment (MCI) is classically considered a transitional stage between normal aging and dementia. Non-amnestic MCI (naMCI) patients, however, typically demonstrate cognitive deficits other than memory decline. Furthermore, as a group, naMCI have a lower rate of an eventual dementia diagnosi...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-015-0143-0

    authors: Coutinho AM,Porto FH,Duran FL,Prando S,Ono CR,Feitosa EA,Spíndola L,de Oliveira MO,do Vale PH,Gomes HR,Nitrini R,Brucki SM,Buchpiguel CA

    更新日期:2015-09-15 00:00:00

  • Compression or expansion of dementia in Germany? An observational study of short-term trends in incidence and death rates of dementia between 2006/07 and 2009/10 based on German health insurance data.

    abstract:INTRODUCTION:There have been recent reports about a decline in dementia incidence, but only little is known about trends in the mortality of patients with dementia. Only the simultaneous analysis of both trends can inform whether the reported decline in dementia has led to a compression of dementia into higher ages. M...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-015-0146-x

    authors: Doblhammer G,Fink A,Zylla S,Willekens F

    更新日期:2015-11-05 00:00:00

  • The association of APOE ε4 with cognitive function over the adult life course and incidence of dementia: 20 years follow-up of the Whitehall II study.

    abstract:BACKGROUND:Approximately 25% of the general population carries at least one ε4 allele of the Apolipoprotein E (APOE ε4), the strongest genetic risk factor for late onset Alzheimer's disease. Beyond its association with late-onset dementia, the association between APOE ε4 and change in cognition over the adult life cour...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-020-00740-0

    authors: Gharbi-Meliani A,Dugravot A,Sabia S,Regy M,Fayosse A,Schnitzler A,Kivimäki M,Singh-Manoux A,Dumurgier J

    更新日期:2021-01-04 00:00:00